Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Rufinamide (Inovelon®) is recommended for use within NHS Wales as an adjunctive therapy in patients four years and older with Lennox-Gastaut syndrome in patients where other adjunctive treatments have proved sub-optimal or have not been tolerated. |
||
|
||
Medicine details |
||
| Medicine name | rufinamide (Inovelon®) | |
| Formulation | 100 mg, 200 mg and 400 mg film-coated tablet | |
| Reference number | 267 | |
| Indication | Adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years and older |
|
| Company | Eisai Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Full | |
| Status | Recommended | |
| Advice number | 1708 | |
| NMG meeting date | 17/09/2008 | |
| AWMSG meeting date | 15/10/2008 | |
| Ratification by Welsh Government | 18/11/2008 | |
| Date of issue | 25/11/2008 | |